

Review

The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease

E Mogilyansky¹ and I Rigoutsos^{*,1}

The miR-17/92 cluster is among the best-studied microRNA clusters. Interest in the cluster and its members has been increasing steadily and the number of publications has grown exponentially since its discovery with more than 1000 articles published in 2012 alone. Originally found to be involved in tumorigenesis, research work in recent years has uncovered unexpected roles for its members in a wide variety of settings that include normal development, immune diseases, cardiovascular diseases, neurodegenerative diseases and aging. In light of its ever-increasing importance and ever-widening regulatory roles, we review here the latest body of knowledge on the cluster's involvement in health and disease as well as provide a novel perspective on the full spectrum of protein-coding and non-coding transcripts that are likely regulated by its members.

Cell Death and Differentiation (2013) 20, 1603–1614; doi:10.1038/cdd.2013.125

Facts

- MiR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92a-1 are members of the miR-17/92 cluster.
- The miR-17/92 cluster is important in cell cycle, proliferation, apoptosis and other pivotal processes.
- The miR-17/92 cluster is important in normal development and also the first group of microRNAs (miRNAs) to be implicated in a human syndrome (Feingold syndrome).
- The miR-17/92 cluster is also known as 'oncomiR-1'.
- The miR-17/92 cluster is very often dysregulated in hematopoietic and solid cancers.
- The miR-17/92 cluster is often dysregulated in cardiovascular, immune and neurodegenerative diseases.
- The miR-17/92 cluster has been implicated in age-related conditions.
- There are two models of miRNA targeting: the 'standard' that has been in use for a decade and the 'expanded' that is emerging with the help of recent technological advances.
- The 'standard' model assumes Watson–Crick pairing in the 'seed' region of a miRNA and targets that are primarily in the 3' untranslated region (3'UTR) and conserved across genomes.

- The 'expanded' model also incorporates Watson–Crick pairing but additionally allows for combinations of unmatched bases and G:U wobbles in the 'seed' region; moreover, the targets can be anywhere along the messenger RNA (not just the 3'UTR) as well as in the intergenic and intronic genomic space; under this model, miRNA targets need not be conserved.

Open Questions

- What currently unsuspected processes and human diseases/conditions are regulated by the miR-17/92 cluster?
- Are there any protein-coding genes that are important for human diseases or conditions and are regulated by the miR-17/92 cluster?
- Does the miR-17/92 cluster have functionally significant genomic targets in the intergenic and intronic parts of the genome?
- Are there additional paralogues of the miR-17/92 cluster that have not yet been reported?
- The presence of guanines and thymines in the seed region of the cluster's members suggests great potential for targeting under the 'expanded' model; what is the relative fraction of the cluster's targets under the 'expanded' model?

¹Computational Medicine Center, Thomas Jefferson University, Philadelphia, PA 19107, USA

*Corresponding author: I Rigoutsos, Computational Medicine Center, Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA 19107, USA. Tel: +1 215 503-6152, Fax: +1 215 503-0466; E-mail: isidore.rigoutsos@jefferson.edu

Keywords: cancer; 'expanded' model of miRNA targeting; microRNA; miRNA; miR-17/92 cluster; oncomir

Abbreviations: 3'UTR, 3' untranslated region; 5'UTR, 5' untranslated region; CLIP-seq, crosslinking and immunoprecipitation followed by high-throughput sequencing; Ago, Argonaute protein; AD, Alzheimer's disease; AML, acute myeloid leukemia; APC, Adenomatous Polyposis Coli; APP, amyloid protein precursor; Atf4, activating transcription factor 4; *C13orf25*, chromosome 13 open reading frame 25; *C. elegans*, *Caenorhabditis elegans*; CAD, coronary artery diseases; CDS, coding sequence; CLL, chronic lymphocytic leukemia; CRC, colorectal cancer; CTGF, connective tissue growth factor; *D. melanogaster*, *Drosophila melanogaster*; ENCODE, the Encyclopedia of DNA Elements; ER, estrogen receptor; IBD, inflammatory bowel diseases; IRES, internal ribosome entry site; IFN γ , interferon- γ ; Isl-1, insulin gene enhancer protein; HC, hepatocellular carcinoma; HSC, hematopoietic stem cells; MAPK 14, mitogen-activated protein kinase 14; M-CSF, macrophage-colony stimulating factor; *MIR17HG*, the miR-17/92 cluster host gene (non-protein coding); miRNAs, microRNAs; MTF, microphthalmia-associated transcription factor; MLL, mixed-lineage leukemia; MS, multiple sclerosis; MSCV, murine stem cell virus; ncRNAs, non-coding RNAs; Nrf2, nuclear factor-erythroid-2-related factor 2; Nts, nucleotides; PTEN, phosphatase and tensin homolog; STAT3, signal transducer and activator of transcription 3; Tbx1, T-box 1 protein; TFs, transcription factors; TNBC, triple negative breast cancer; TSP-1, thrombospondin-1; VHL, von Hippel-Lindau tumor suppressor

Received 29.4.13; revised 15.7.13; accepted 19.7.13; Edited by G Melino




Figure 2 Members of the miR-17/92 cluster and its two paralogues miR-106a/363 and miR-106b/25 and their chromosomal location. Red: members of the miR-17 family; blue: members of the miR-18 family; green: members of the miR-19 family; orange: members of the miR-92 family

miR-17 family	hsa-miR-17-5p	C AAAGUC CUUACAGUGCAGGUAGU
	hsa-miR-20a-5p	U AAAGUC CUUUAUGUGCAGGUAG
	hsa-miR-20b-5p	C AAAGUC CUCAUAGUGCAGGU
	hsa-miR-106a-5p	C AAAGUC CUAACAGUGCAGGU
	hsa-miR-106b-5p	U AAAGUC CUGACAGUGCAGU
hsa-miR-93-5p	C AAAGUC CUGUUCGUGCAGGUAG	
miR-18 family	hsa-miR-18a-5p	U AAGGUC CAUCUAGUGCAGUA
	hsa-miR-18b-5p	U AAGGUC CAUCUAGUGCAGUA
miR-19 family	hsa-miR-19a-3p	U GUGCAA AUCUAUGCAAACUGA
	hsa-miR-19b-3p	U GUGCAA AUCCAUGCAAACUGA
	hsa-miR-19b-3p	U GUGCAA AUCCAUGCAAACUGA
miR-92 family	hsa-miR-92a-3p	U AUUGCA CUUGUCCCGGCCUG
	hsa-miR-92a-3p	U AUUGCA CUUGUCCCGGCCUG
	hsa-miR-25-3p	C AUUGCA CUUGUCUCGGUCUGA
	hsa-miR-363-3p	A AUUGCA CGGUUCCAUCUGUAG

Figure 3 Sequences of the members of the miR-17/92 cluster (in bold face) and its two paralogues miR-106a/363 and miR-106b/25. The sequences are divided into four families according to the miRNA 'seed' (the sequence spanning positions 2 through 7 inclusive counting from the 5' end of the miRNA). The 'seed' in each case is shown in boldface and is highlighted in blue

E2F1 and E2F3.^{19,20} The data show close functional interactions between c-Myc/n-Myc and the miR-17/92 cluster. Both c-Myc and n-Myc can directly bind to the promoter of miR-17/92 and initiate transcription.^{17,21,22} Indeed, some patients with an N-MYC mutation have developmental abnormalities similar to those in Feingold syndrome patients (see below).^{23,24}

Additional information on transcriptional regulation became available through the recent release by the ENCODE (Encyclopedia of DNA Elements) project²⁵ of data from the study of 118 transcription factors (TFs). ENCODE's results revealed 1292 TF:miRNA interactions and 421 miRNA:TF interactions that in turn suggest tightly coupled auto-regulatory loops involving miRNAs and TFs. Of the 118 TFs, 34 pertain to the miR-17/92 cluster: they include the previously known MYC^{17,18} and MXI^{26,27} and 32 novel TFs (Figure 4). Among the newly identified TFs, BCL3 was found to regulate miR-17/92 and miR-106b/25. Further, BCL3, IRF1, SP1, TAL1 and ZBTB33 are targeted by individual miRNAs of the cluster, in addition to being TFs for the cluster (Figure 4). Moreover, several novel targets for members of miR-17/92 and miR-106b/25 were identified and are also summarized in Figure 4.^{25,28} With regard to the miR-106a/363 cluster, it is likely regulated by the microphthalmia-associated transcription factor (MITF) through a binding site at position 133,135,780 (hg19) of chromosome X in the cluster's immediate vicinity.²⁹

Among TFs, the E2F family (E2F1, E2F2 and E2F3) have a central role in the regulation of G1 to S phase progression.³⁰ All E2Fs,^{17,19} especially E2F3,²⁰ have been shown to occupy miR-17/92's promoter region. E2Fs are also known to be targeted by miR-17/92, forming an auto-regulatory loop (Figure 4).^{19,20} Finally, recent studies indicate that TP53 targets the miR-17/92 cluster³¹ while also being targeted by miR-25 through regulation of the latter by Myc and E2F1.³²

Despite these significant advances, knowledge about the transcriptional control of miR-17/92 and its paralogues remains largely fragmentary. It is also important to note that the specific processing of individual miRNAs adds a new level of complexity; that is, it is conceivable that there is a cell-type-dependent and context-dependent dimension to post-transcriptional silencing.^{14,15,33,34}

Main Targets of the miR-17/92 Cluster

Phosphatase and tensin homolog (*PTEN*) and *E2Fs* were among the first validated miR-17/92 targets.^{15,17,19} Reporter assays revealed targets for miR-19a and miR-19b-1 in *PTEN*'s 3'UTR, and the introduction of miR-19a and miR-19b-1, or of the full cluster, in miR-17/92-deficient cells sufficed to restore *PTEN* expression levels.¹⁵ In addition, miR-17 and miR-20a modulate the expression of *E2F1*.^{17,19} Lastly, miR-20a targets the 3'UTRs of both *E2F2* and *E2F3* (Figure 4).¹⁹

The ability of the cluster's members to cooperate is evident in the context of TGF- β signaling. In particular, miR-17 and miR-20a directly target the TGF- β receptor II (*TGFBRII*), whereas miR-18a targets Smad2 and Smad4, two members of the TGF- β signaling pathway.³⁵⁻³⁷ TGF- β activation exerts an effect mediated in part by the cyclin-dependent kinase inhibitor (p21) and the apoptosis facilitator BCL2L11 (BIM), both of which are targeted by miR-17/92.^{35,38} In addition, BCL2L11 is targeted by miR-20a, miR-92, miR-19a and miR-19b-1¹⁵ and also by miR-106b/25.³⁹ During the endoplasmic reticulum related stress, unfolded protein response TFs, activating TFs, activating transcription factor 4 (Atf4) and nuclear factor-erythroid-2-related factor 2 (Nrf2) are activated and downregulate *Mcm7*, the host gene for the miR-106a/25 cluster. Downregulation of miR-106b/25 and repression of *BCL2L11* consequently trigger apoptosis.³⁹

Lastly, miR-18a and miR-19 directly repress the anti-angiogenic factors thrombospondin-1 (*TSP-1*) and connective




Figure 4 The transcriptional regulation and main targets of the miR-17/92 cluster and its paralogues. The transcriptional factors (TFs) in the left upper corner have been functionally validated; dark blue arrows indicate upregulation; black lines indicate repression. TFs in the blue 'cloud' were identified by the ENCODE project and the relationship of most of them to the miR-17/92 cluster and its paralogues is putative. Blue TFs were validated previously and confirmed by ENCODE; red TFs putatively regulate the miR-17/92 cluster and at the same time are known to be targeted by cluster members; green TFs putatively regulate the miR-17/92 cluster and at the same time are known to be targeted by paralogue miR-106b/25. If the specific gene that is targeted by a miRNA is known, the repressor line ends at the gene; otherwise, it ends at the box boundary of the respective cell process

tissue growth factor (*CTGF*).⁴⁰ In addition, miR-17 and miR-20a participate in the regulation of the insulin gene enhancer protein (*Isl-1*) and the T-box 1 protein (*Tbx1*) (Figure 4).⁴¹

MiR-17/92 and Normal Development

The miR-17/92 cluster is highly expressed in embryonic cells¹⁵ and has an important role in development.

MiR-17/92 was the first group of miRNAs to be implicated in a developmental syndrome in humans. Indeed, studies of patients with Feingold syndrome revealed an important role for the miR-17/92 cluster in normal skeletal development.²⁴ Human patients with heterozygous microdeletions in the *MIR17HG* locus have autosomal dominant Feingold syndrome, characterized by multiple skeletal abnormalities in the fingers and toes, short stature and microcephaly. Some patients also show various degrees of learning and developmental disabilities.²⁴

Subsequent mouse studies showed that deletion of the miR-17/92 cluster is perinatal lethal.¹⁵ MiR-17/92^{-/-} embryos exhibit severe skeletal abnormalities and recapitulate the phenotype observed in patients with Feingold

syndrome. The mice are also smaller in size than normal embryos, and die at birth from cardiac defects and lung hypoplasia.^{15,22} The miR-17/92 cluster is involved also in normal lung morphogenesis, epithelial proliferation and branching through the targeting of signal transducer and activator of transcription 3 (*STAT3*) and mitogen-activated protein kinase 14 (*MAPK14*).⁴² The overexpression of the miR-17/92 cluster leads to lung epithelium hyper-proliferation and suggests a role in lung cancer.⁴³

Analogously to the miR-17/92 studies that indicated a role in B-cell differentiation, the normal process of B-cell maturation in miR-17/92^{-/-} mice is blocked during the progression from pro-B to pre-B cells. Mice with a deleted miR-17/92 cluster have a reduced number of pre-B cells at E18.5.¹⁵ In experiments with adult mice whose hematopoietic system is reconstituted with fetal liver cells from a miR-17/92^{Δneo/Δneo} embryo at E14.5, the number of circulating lymphocytes, circulating B cells, splenic B cells and pre-B-cells bone marrow cells is significantly reduced compared with mice with reconstituted fetal liver cells from wild-type embryos at 8–10 weeks post transplant.¹⁵ Mice that were irradiated and had their hematopoietic system reconstituted with hematopoietic

stem cells (HSC) derived from fetal liver of Eμ-myc transgenic mice expressing miR-17/19 under the control of murine stem cell virus (MSCV) show a massive enlargement of lymph nodes, splenic hyperplasia, infiltration of the thymus by lymphoma cells and leukemias.¹³ Moreover, almost half of the animals in the test group exhibited hind leg paralysis as the result of tumors at the lumbar node. These results suggest the importance of miR-17/92 in normal B-cell development and survival. On the other hand, overexpression of the cluster was also shown to cause lymphoproliferative diseases.⁴⁴

Parallel studies have also implicated miR-17/92 in normal lymphocyte development.⁴⁵ In mouse knockout models, miR-19b-1 and miR-17 were shown to promote T-cell expansion; the mice display reduced lymphocyte proliferation that was attributed to the promotion of interferon-γ (IFNγ) production by miR-19b-1 and the promotion of a Th1 response by miR-17 and miR-19b-1.⁴⁵ Indeed, miR-17 and miR-19b-1 have an important role in promoting B-cell proliferation, protecting B-cells from death, supporting IFNγ production and suppressing T-cell differentiation.⁴⁵

The Cluster as an Oncogene

We next review the increasing body of literature on the cluster's oncogenic role (Table 1).^{46,47}

B-cell Lymphomas

The miR-17/92 cluster was initially found amplified in diffuse cell lymphomas.⁹ Later, in B-cell lymphoma, an ectopically overexpressed truncated version that lacked miR-92 showed the cluster's role as an oncogene.¹³ Moreover, as already discussed, c-Myc was shown to transcribe the truncated cluster in mouse models of B-cell lymphoma.¹³ These findings represent early evidence that miR-17/92 can act as an oncogene by suppressing apoptosis.¹³ MiR-18a levels in diffuse large B-cell lymphoma correlate strongly and negatively with survival (higher expression-shorter survival).⁴⁸ As mentioned already, miR-19a and miR-19b-1 are necessary and sufficient to promote tumorigenesis B-cell lymphoma.^{49–51} In addition, the conditional knockout of miR-17/92 in Myc-driven lymphomas was shown to increase apoptosis and to reduce tumorigenicity and tumor progression.⁴⁹

B-cell Chronic Lymphocytic Leukemia

MiR-20a was found to correlate with diagnosis to treatment time in B-cell chronic lymphocytic leukemia (CLL) and thus can potentially serve as a blood biomarker.⁵² The cluster members miR-17 and miR-19b-1 are highly overexpressed in CLL cultures with fibroblast expressing human CD40 ligand (CD154) with IL-4. Another study found miR-20, miR-18a, miR-

Table 1 Relative expression of individual miRNAs from the miR-17/92 cluster or its paralogues in normal development, cancer, other diseases and age-related conditions

miRNA	Normal skeletal formation/Feingold syndrome	Lung and heart development	B-cell development	T-cell development	B-cell lymphoma	Diffuse large B-cell lymphoma	B-cell CLL	MLL-rearrangements	AML t (8;21)	AML t (15;17)	T-cell lymphoma	T-cell ALL	Multiple myeloma	Retinoblastoma	Colorectal cancer	Head and neck cancer	Pancreatic cancer	Breast cancer	Ovarian cancer	Lung cancer	Renal cancer	Hepatocellular carcinoma	Osteosarcoma	Gastric cancer	Nasopharyngeal cancer	Urothelial cancer	Autoimmunity	Cardiovascular diseases	Alzheimer's disease	Multiple sclerosis	Aging		
miR-17	!	!	!	!	↑	↑	↑	↑	↓	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↓	↓	↓		
miR-18a	!	!			↑	↑	↑			↑					↑	↑	↑	↑		↑	↑	↑			↑	↑			↑				
miR-19a	!	!			↑	↑	↑			↑					↑	↑	↑	↑		↑	↑	↑				↑	↑						
miR-20a	!	!			↑	↑	↑	↑	↓	↓	↑		↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑			↑	↑		↓	↓	↓		
miR-19b-1	!	!	!	!	↑	↑	↑				↑	↑			↑	↑	↑	↑			↑	↑				↑	↑			↓			
miR-92a-1	!	!			↑	↑	↑		↓		↑		↑		↑	↑		↑			↑	↑				↑	↑		↓				
miR-106a								↑																					↓	↓			
miR-106b								↑											↑			↑							↓	↑			
miR-18b																		↑															
miR-93																						↑											
miR-25																						↑									↑		

Notation: !: expression of miRNAs is important for normal development; ↑: over-expressed miRNAs; ↓: under-expressed miRNAs; blue boxes: normal development; burgundy boxes: hematopoietic cancers; green boxes: solid cancers; violet boxes: other diseases; orange boxes: age-related conditions. Gray cells indicate inconclusive evidence or unavailable data.

19a and miR-92a to be overexpressed in CLL cultures, but at much lower levels than those of miR-17 and miR-19b-1.⁵³

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous group of diseases with different genetic rearrangements, different prognosis and required treatment options. MiR-17-5p, miR-17-3p, miR-20a and miR-92 are upregulated in myeloid/lymphoid, or mixed-lineage leukemia (MLL), display rearrangements in AML and are downregulated in AML with the translocation t(8;21). On the other hand, miR-17-5p and miR-20a are downregulated in t(15;17). AML with MLL-rearrangements is considered to have intermediate or poor prognosis; moreover, it requires a different treatment from AML with t(8;21)/t(15;17) that usually carries a favorable prognosis.⁵⁴ In mouse studies, the levels of miR-106 were found to be upregulated in AML and to target Sequestosome 1 (*SQSTM1*).⁵⁵ In AML characterized by the translocation t(8;16)(p11;p13), miR-17/92 is downregulated.⁵⁶ However, there is no significant difference in the expression of *MYC* between t(8;16)(p11;p13) AML and other types of AML suggesting that other mechanisms of downregulation, for example, methylation, may be at work.⁵⁶

T-cell Lymphoma

In an experiment with the SL3-3 murine leukemia virus, 2545 BALB/c newborn mice were infected and nearly all developed T-cell lymphoma. Quantitative RT-PCR analysis showed elevated expression of miR-17/92 after virus integration.⁵⁷ The miR-17/92 integration sites were found to cluster together at three distinct regions; the integration sites within each such region were ~1 kb apart.⁵⁷

Retinoblastoma

Overexpression and genomic amplification of miR-17/92 were shown in retinoblastoma.⁵⁸ In particular, in *Rb*^{-/-} and *p107*^{-/-} retinoblastomas, ectopic expression of miR-17/92 induces rapid proliferation and disease onset. This increase in proliferation is linked to the miR-17 sub-family, which target the cell cycle inhibitors *p21*^{Cip1} and *p57*^{Kip2}.^{58,59}

Colorectal Cancer

MiR-17/92 was also found overexpressed in colon cancer.⁴⁰ In a tumor engraftment model, upregulation of the cluster by *Myc* in colonocytes increased tumorigenesis by promoting angiogenesis through direct repression of *TSP-1* and *CTGF* by miR-18a and miR-19, respectively.⁴⁰ MiR-18a and miR-20a are significantly overexpressed in colorectal cancer (CRC); in fact, miR-18a is a marker of poor prognosis.⁶⁰ In addition, miR-92 levels in colon adenocarcinoma have been shown to correlate negatively with *BCL2L11* expression and, thus, with reduced apoptosis.⁶¹ High miR-17 expression correlates with low overall survival in patients with CRC.⁶² Another study that comprised 90 patients with CRC, 90 patients with inflammatory bowel diseases (IBD), 20 patients with gastric cancer and 50 healthy controls also confirmed high

expression level of miR-17 and miR-92 in tumors and serum from patients with CRC.⁶³ Patients with CRC had higher miR-92 levels compared with healthy controls or patients with IBD or gastric cancer.⁶³ Interestingly, results revealed a correlation between miR-18a expression and Adenomatous Polyposis Coli (*APC*) mutation in CRC samples.⁶⁴

Head and Neck Cancers

MiR-17/92 is often overexpressed in medulloblastomas, especially those with an active Sonic hedgehog signaling pathway. The cluster is overexpressed in mouse models in cerebellar granule neuron progenitors, where the tumor arises.^{65,66} Ectopic expression of miR-17/92 increases tumor formation through the suppression of TGF- β signaling upon orthotopic transplantation into immunocompromised mice.^{65,66} These studies suggest a tissue-specific function for members of the miR-17/92 cluster. The miR-17/92 cluster amplification was also reported in neuroblastomas and is linked to poor prognosis.⁶⁷ Lastly, miR-17 has been shown to promote the growth of neuroblastoma cell lines.⁶⁸

Pancreatic Cancer

In pancreatic cancer, miR-17, miR-18a, miR-19a and miR-19b-1 expression levels are increased.^{69,70} Another study also showed that the level of miR-18a in the blood is significantly higher before surgery in patients with pancreatic cancer compared with after surgery, suggesting the possibility that blood levels of miR-18 can potentially be used as a biomarker.⁷⁰

Breast Cancer

Deep sequencing of triple negative breast cancer (TNBC) samples revealed a threefold increase of miR-17/92 levels.⁷¹ In estrogen receptor (ER)-positive breast cancer, it was shown that miR-18a/18b directly target the 3'UTR of the ER α .⁷² In addition, miR-17 and miR-20 are overexpressed in metastatic breast cancer⁷³ and have been shown to directly suppress the 3'UTR of IL-8 and to inhibit cytokeratin 8 through cyclin D1.⁷³ Another study has shown that miR-106b positively correlates with homeotic TF Six1 expression levels in breast cancer.⁷⁴ Six1 depends on the upregulation of the TGF- β pathway to induce epithelial-mesenchymal transition. In addition, high levels of miR-106b are indicative of shorter time to relapse.⁷⁴

Ovarian Cancer

Studies have implicated the overexpression of miR-20a in proliferation and invasion in the OVCAR3 cell line, whereas the downregulation of miR-20a has been shown to lead to the suppression of proliferation and invasion. A possible mechanism is through binding to the amyloid protein precursor (APP), a gene of central importance in Alzheimer's disease (AD).⁷⁵

Lung Cancer

In lung cancer, miR-17-5p and miR-20a are overexpressed.⁷⁶ Their targets include *HIF-1 α* , *PTEN*, *BCL2L11*, *CDKNA* and *TSP-1*.⁷⁶ A study of 221 lung cancer patients and 54 matching controls showed a significant increase of miR-17-5p expression in tumor and serum and a negative correlation with patient survival.⁷⁷ However, the blood of non-small cell lung cancer patients had a low level of miR-17-5p.⁷⁸

Renal Cancer

The miR-17/92 cluster is regulated by the von Hippel-Lindau (VHL) tumor suppressor: in the absence of VHL, miR-17/92 levels increase.⁷⁹ Other studies have shown miR-17, miR-18a and miR-20a to be overexpressed in renal cancer; however, overexpression of these miRNAs did not correlate with survival.^{80,81}

Hepatocellular Carcinoma

All six members of the miR-17/92 cluster are often overexpressed in hepatocellular carcinoma (HC).⁸² The use of antisense nts specific to all six members of the miR-17/92 cluster caused a 50% reduction in proliferation and anchorage-independent growth.⁸² In addition, several members of miR-17/92 and its paralogues (miR-92,⁸³ miR-18a, miR-106b, miR-93 and miR-25⁸⁴) are highly expressed in HC cells compared with paired non-tumor samples. Another study showed that miR-18, and the miR-106b/25 paralogue, was overexpressed in 50% of clinical samples used in the study.⁸⁴ Cell culture studies have also shown that the knockdown of miR-106b/25 leads to decreased cell proliferation and anchorage-independent growth in three different cell lines: HepG2, HeLa and HuH7.⁸⁴

Osteosarcoma

MiR-17/92 is overexpressed in osteosarcoma as demonstrated by luciferase assays.⁸⁵ In particular, miR-17 and miR-20a are overexpressed in metastasized cells compared with parental cells.⁸⁶ In addition, mouse studies with anti-miR-20a showed significant increase in lung metastases, possibly through the repression of FasL in the lung tissues.⁸⁶

The Cluster in Other Diseases

Beyond cancer, the miR-17/92 cluster has been shown to have important roles in other human conditions including immune, cardiovascular and neurodegenerative diseases.^{87–90}

Immune Diseases

The miR-17/92 cluster has a role in the innate and acquired immune response.⁸⁸ In human cord blood, CD34 + hematopoietic progenitor cells differentiate into monocytes upon exposure to macrophage-colony stimulating factor (M-CSF) and the miR-17/92 cluster.⁹¹ MiR-17/92 also has a role in the acquired immune response.⁸⁸ Another study has shown that autoimmunity, characterized by increased proliferation and survival of CD4 + T cell, could be caused by overexpression of the miR-17/92 cluster in the DN1 stage.⁸⁸

Cardiovascular Diseases

MiR-92a is highly expressed in endothelial cells but overexpression of miR-92a in those cells under ischemic conditions was shown to inhibit angiogenesis.⁹² In a mouse model with leg ischemia, the administration of antagomiR-92a led to inhibition of miR-92a with consequent growth of new blood vessels and recovery from ischemia.⁹² In another study, endothelial cells from patients with coronary artery disease (CAD) exhibited higher levels of miR-17 and miR-92a compared with endothelial cells from healthy controls.^{93,94} In another study, the miRNA profile of patients with acute coronary syndrome showed an increase of miR-19 compared with patients with CAD.⁹⁵ And a study of miRNA levels measured by quantitative RT-PCR in whole blood and serum showed reduced miR-19a levels in patients with CAD compared with healthy controls.

Neurodegenerative Diseases

The amyloid precursor protein APP generates the amyloid- β , A β , peptide through the 'amyloidogenic' pathway with the help of β - and γ -secretases. A β accumulates in extracellular spaces forming A β plaques. Members of the miR-17 family (i.e., miR-17, miR-20a, miR-106a and miR-106b) were shown to directly suppress APP *in vitro*.^{96,97} In the AD brain, miR-106b was shown to be downregulated *in vivo*.⁹⁷

In relapsing patients with multiple sclerosis (MS), miR-18 was found to be overexpressed compared with controls.⁹⁸ Another study of CD4 + T cells and B cells of relapsing and remitting MS patients shows the upregulation of miR-17-5p in CD4 + T cells and downregulation of miR-92 in B cells.⁹⁹ Another study has shown under-expression of miR-17 and miR-20a in whole-blood samples from 59 MS patients compared with 37 healthy controls.¹⁰⁰ The MS patients represented different disease types (primary progressive, secondary progressive and relapsing-relapsing) and for the last 3 months before the study had not received any treatment. In addition, miR-106b and miR-25 were found to be upregulated in 12 relapsing-remitting MS patients and in 14 healthy controls.¹⁰¹ A recent analysis used an integrative approach to study miRNAs dysregulated in MS revealed that miR-20a and miR-20b target ~500 genes each.¹⁰²

On a related note, profiling of miRNA expression in the brain of zebrafish (*Danio rerio*) showed that miR-92 is expressed in periventricular cells and in proliferative zones of larva and adult brain and down-regulated in mature neurons.¹⁰³

The Cluster and Age-Related Conditions

Considering the importance of miR-17/92 in tumorigenesis, it was not long before the relation between dysregulation of these miRNAs and aging was discovered.^{104,105} Studies of different tissue types representing aging revealed downregulation of miR-17, miR-19b, miR-20a and miR-106a.¹⁰⁶ This suggests yet another role for these miRNAs, one that transcends cell cycle regulation and tumorigenesis. However, the mechanistic connection between downregulation of the cluster's members and aging has yet to be elucidated.¹⁰⁵

The Potentially Wide Spectrum of Coding and Non-coding Sequences Targeted by the Cluster

It should be clear by now that the cluster's members are involved in very diverse settings and a wide range of post-transcriptional regulatory events. The experimental findings to date about the cluster's targetome have been driven primarily by the analyses of gene-expression array data. The exact mechanistic aspects of those interactions have been elucidated in only relatively few contexts. To better appreciate the range of possibilities and to place the cluster's known (and unknown) targets in the appropriate light, it is important to first review briefly how miRNA target prediction has been practiced.

A miRNA effects the post-transcriptional regulation of its targets in a sequence-dependent manner. The 'seed' in particular, that is, the sequence spanning positions 2–7 inclusive from the 5' end of a miRNA, is especially important for target determination and coupling.^{1,5,107–113} Early genetic studies and subsequent efforts demonstrated that miRNAs can function in the presence of inexact matches and/or bulges in the seed region.^{108,109,111,114–125} Despite the potential diversity of targets, there has been a strong adherence throughout to a 'standard' model that anticipates exact base-pairing, that is, Watson–Crick, and the absence of any bulges in the seed region. Consequently, the majority of the designed algorithms treated these criteria as necessary and sufficient attributes of *bona fide* targets and combined them with the enforcement of cross-genome conservation. However, algorithms were also proposed that neither enforced nor used these constraints, for example, rna22.¹²⁶ As a matter of fact, rna22 permits Watson–Crick and G:U pairs in the seed region as well as bulges; moreover, a candidate target does not have to be conserved across organisms and can be located anywhere.

An additional element, likely guided by the early *C. elegans* studies with the 3'UTR of the *lin-14* and *lin-41* genes, relates to an adherence to seek miRNA targets primarily in the 3'UTR of the candidate mRNAs. Nevertheless, the use of artificial constructs demonstrated the absence of any mechanistic constraints that would prevent the targeting of other mRNA regions by miRNAs: let-7 target sites embedded in the coding sequence (CDS) were shown to be functional.¹²⁷ Analogously, the introduction of miRNA target sites into the 5'UTR of luciferase reporter mRNAs containing internal ribosome entry sites (IRESs) revealed that miRNAs could regulate the abundance of a target by binding to its 5'UTR.¹²⁸

Further support for these findings came more recently through a number of efforts by our group and others that reported the discovery and validation of extensive and naturally occurring miRNA targets in the CDS of an mRNA as well as its 5'UTR.^{129–134} In earlier work, we estimated that as many as 90% of the known protein-coding human genes could be targeted by miRNAs.¹²⁶ On a related note, miRNAs were recently shown to also target intergenic and intronic regions, pseudogenes and long ncRNAs.^{119,121,123,135,136}

Another dimension of the miRNA target prediction problem relates to the observation of conservation of miRNA sequences across animals and plants (and viruses). At the

sequence level, most miRNAs are evolutionarily conserved among distant species.¹³⁷ However, not every known miRNA is conserved: indeed, there are reports of miRNAs that are species- or genus-specific.^{138,139} Moreover, it is known that conserved miRNAs do not have the same functional behavior in different species: let-7, which is conserved between *C. elegans* and *Drosophila melanogaster*, is a characteristic example. In the worm, let-7 is a component of the heterochronic pathway; it is expressed at a late stage of larva development, regulates the transition from larva to adult⁵ and is embryonic lethal.¹⁴⁰ In the fruit fly, let-7-knockout flies are externally normal but exhibit behavioral defects and juvenile features in their neuromusculature.¹⁴¹

In recent work¹¹³ we used molecular dynamics to analyze the crystal structure of the Argonaute (Ago) silencing complex and demonstrated in a very general way the existence of many admissible targets that transcend the 'standard' model that has been in use for more than a decade already. The molecular dynamics findings were further corroborated by publicly available Ago-immunoprecipitated¹¹⁹ and sequenced miRNA targets.¹¹³ These results provide strong evidence in support of an expanded model of miRNA targeting and are very relevant for the members of the miR-17/92 cluster and for our estimates of this cluster's targetome (Figure 5). Glimpses of evidence supporting the 'expanded' model were also observed experimentally in earlier work^{109,111,116–118} as well as discussed in the literature.^{110,112,124,130,142}

The members of miR-17/92 clusters are ideal miRNAs for which to explore 'unexpected targets' under the 'expanded' model. Indeed, as all of the members have at least two G/U bases in their seed region, (Figure 3) they could potentially base pair with U and G, respectively, on the side of the target to create wobbles and additional targets (Figure 5). In addition, potential incorporation of bulges on either the miRNA or the target side would lead to an even higher number of non-standard targets.

There is also increasing evidence with regard to non-protein-coding transcripts that could be targeted by miRNAs. The evidence comes both from studies of individual miRNA:target pairs as well as global analyses. In particular, it has already been shown for several miRNAs, some belonging to the miR-17/92 cluster, that they target and suppress the expression of *PTENP1*, the *PTEN* pseudogene.^{143,144} The same study also showed targeting and regulation by miRNAs of the *KRAS* pseudogene *KRAS P1* as well as of several of the pseudogenes of *OCT4*. More recently,¹³⁶ it was shown that miR-133 and miR-135 target a long non-coding RNA, linc-MD1, thereby regulating the expression of *MAML1* and *MEF2C*, two TFs that activate muscle-specific gene expression. In addition, the advent of the crosslinking and immunoprecipitation followed by high-throughput sequencing (CLIP-seq) technology has enabled global studies of miRNA targeting preferences in a variety of contexts.^{119,123,145–147} Initial analyses of the available data have provided additional evidence that miRNA-targeted transcripts include numerous transcripts that are not protein-coding.¹¹³

These findings indicate that the miR-17/92 targetome may be larger and further ranging than originally anticipated. As we saw above, several members of the miR-17/92 cluster have




Figure 5 Differences between the ‘standard’ and ‘expanded’ model of miRNA targeting and the corresponding targetome. The seed of miR-18 is used as an example (bases at positions 2 through 7 inclusive). For the expanded model’s G:U wobble examples and bulge examples, only a few representative cases are shown

been implicated in the regulation of non-protein-coding transcripts. In addition, the sequence composition of the seed region of the cluster’s members and in particular the presence of G/U’s in the seed provides them with an expanded base-pairing ability. Consequently, there is great potential that a very rich set of currently unrecognized heteroduplexes comprising miRNAs of the miR-17/92 cluster awaits discovery.

Conclusion

MiR-17/92 is one of the best-known miRNA clusters. The cluster’s members have pivotal roles in normal development, and dysregulation of their expression leads to a wide array of diseases including hematopoietic and solid cancers, and immune, neurodegenerative and cardiovascular diseases. The cluster is also important because its members are the first described in the context of a developmental syndrome in humans. Related to this, other recent work uncovered novel important connections between the miR-17/92 cluster and aging.

Despite great progress in understanding the cluster’s roles, several key questions remain unanswered. For example, until the recently reported findings by the ENCODE project very little was known about the transcriptional control of the cluster by TFs as well as about the targeting of TFs by members of the cluster and its paralogues. Considering the ENCODE

project’s findings, it is reasonable to conjecture that the actual transcription control of the cluster is significantly more complex than research to date has managed to reveal.

A parallel and very important question is that of elucidating the cluster’s targetome. The currently known set of validated protein-coding targets is small. In light of the many miRNAs that the cluster and its paralogues comprise and the recent evidence obtained through molecular dynamics studies and CLIP-seq data analyses, it is increasingly apparent that the true spectrum of targets is potentially very large. Additional research effort will be needed before the full complement of the cluster’s targets can be elucidated. It is also important to note that an increased target set opens up new opportunities and new avenues for therapeutic intervention in those settings, where one or more of the cluster’s members are dysregulated.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements. We thank Eric Londin for feedback on an earlier version of the manuscript, Peter Clark for suggestions with some figures and the other members of the Rigoutsos laboratory for helpful discussions. This research was supported in part by the William M Keck Foundation (IR), the Hirshberg Foundation for Pancreatic Cancer Research (IR) and by institutional funds.

1. Bartel DP. Micromas: genomics, biogenesis, mechanism, and function. *Cell* 2004; **116**: 281–297.
2. Bartel DP. Micromas: target recognition and regulatory functions. *Cell* 2009; **136**: 215–233.
3. Ambros V. A hierarchy of regulatory genes controls a larva-to-adult developmental switch in *C. elegans*. *Cell* 1989; **57**: 49–57.
4. Ruvkun G, Giusto J. The *Caenorhabditis elegans* heterochronic gene *lin-14* encodes a nuclear protein that forms a temporal developmental switch. *Nature* 1989; **338**: 313–319.
5. Reinhart BJ, Slack FJ, Bassom M, Pasquinelli AE, Bettinger JC, Rougvie AE *et al.* The 21-nucleotide *let-7* miRNA regulates developmental timing in *Caenorhabditis elegans*. *Nature* 2000; **403**: 901–906.
6. Chang S, Johnston RJ Jr, Frokjaer-Jensen C, Lockery S, Hobert O. Micromas act sequentially and asymmetrically to control chemosensory laterality in the nematode. *Nature* 2004; **430**: 785–789.
7. Johnston RJ, Hobert O. A micromas controlling left/right neuronal asymmetry in *Caenorhabditis elegans*. *Nature* 2003; **426**: 845–849.
8. Brennecke J, Cohen SM. Towards a complete description of the micromas complement of animal genomes. *Genome Biol* 2003; **4**: 228.
9. Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S *et al.* Identification and characterization of a novel gene, *c13orf25*, as a target for 13q31-q32 amplification in malignant lymphoma. *Cancer Res* 2004; **64**: 3087–3095.
10. Mendell JT. Miriad roles for the miR-17-92 cluster in development and disease. *Cell* 2008; **133**: 217–222.
11. Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, Mongera S, Postma C, Meijerink WJ *et al.* Mir-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. *Br J Cancer* 2009; **101**: 707–714.
12. Concepcion CP, Bonetti C, Ventura A. The micromas-17-92 family of micromas clusters in development and disease. *Cancer J* 2012; **18**: 262–267.
13. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S *et al.* A micromas polycistron as a potential human oncogene. *Nature* 2005; **435**: 828–833.
14. Houbaviy HB, Murray MF, Sharp PA. Embryonic stem cell-specific micromas. *Developmental Cell* 2003; **5**: 351–358.
15. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ *et al.* Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of micromas clusters. *Cell* 2008; **132**: 875–886.
16. Barski A, Jothi R, Cuddapah S, Cui K, Roh YH, Schones DE *et al.* Chromatin poises micromas- and protein-coding genes for expression. *Genome Res* 2009; **19**: 1742–1751.
17. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. C-myc-regulated micromas modulate *e2f1* expression. *Nature* 2005; **435**: 839–843.
18. Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC *et al.* Myc regulates oncogenic micromas in neuroblastoma. *Int J Cancer* 2008; **122**: 699–704.
19. Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F *et al.* An *e2f1/mir-20a* autoregulatory feedback loop. *The Journal of biological chemistry* 2007; **282**: 2135–2143.
20. Woods K, Thomson JM, Hammond SM. Direct regulation of an oncogenic micromas cluster by *e2f* transcription factors. *J Biol Chem* 2007; **282**: 2130–2134.
21. Loven J, Zinin N, Wahlstrom T, Muller I, Brodin P, Fredlund E *et al.* Myc-regulated micromas repress estrogen receptor- α (*esr1*) expression and neuronal differentiation in human neuroblastoma. *Proc Natl Acad Sci USA* 2010; **107**: 1553–1558.
22. de Pontual L, Yao E, Callier P, Faivre L, Drouin V, Cariou S *et al.* Germline deletion of the miR-17 approximately 92 cluster causes skeletal and growth defects in humans. *Nature Genet* 2011; **43**: 1026–1030.
23. van Bokhoven H, Celli J, van Rееuwijk J, Rinne T, Glaudemans B, van Beusekom E *et al.* Myc haploinsufficiency is associated with reduced brain size and intestinal atresias in feingold syndrome. *Nature Genet* 2005; **37**: 465–467.
24. Marcelis CL, Hol FA, Graham GE, Rieu PN, Keller Mayer R, Meijer RP *et al.* Genotype-phenotype correlations in myc-related feingold syndrome. *Hum Mut* 2008; **29**: 1125–1132.
25. Gerstein MB, Kundaje A, Hariharan M, Landt SG, Yan KK, Cheng C *et al.* Architecture of the human regulatory network derived from encode data. *Nature* 2012; **489**: 91–100.
26. Ji M, Rao E, Ramachandrarreddy H, Shen Y, Jiang C, Chen J *et al.* The miR-17-92 micromas cluster is regulated by multiple mechanisms in b-cell malignancies. *Am J Pathol* 2011; **179**: 1645–1656.
27. Kim K, Chadalapaka G, Lee SO, Yamada D, Sastre-Garau X, Defossez PA *et al.* Identification of oncogenic micromas-17-92/zbtb4/specificity protein axis in breast cancer. *Oncogene* 2012; **31**: 1034–1044.
28. Korolov SB, Muljo SA, Galler GR, Krek A, Chakraborty T, Kanellopoulou C *et al.* Dicer ablation affects antibody diversity and cell survival in the b lymphocyte lineage. *Cell* 2008; **132**: 860–874.
29. Oszolak F, Poling LL, Wang Z, Liu H, Liu XS, Roeder RG *et al.* Chromatin structure analyses identify micromas promoters. *Genes Dev* 2008; **22**: 3172–3183.
30. Muller H, Helin K. The *e2f* transcription factors: Key regulators of cell proliferation. *Biochim Biophys Acta* 2000; **1470**: M1–12.
31. Yan HL, Xue G, Mei Q, Wang YZ, Ding FX, Liu MF *et al.* Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. *EMBO J* 2009; **28**: 2719–2732.
32. Suh SS, Yoo JY, Nuovo GJ, Jeon YJ, Kim S, Lee TJ *et al.* Micromas/tp53 feedback circuitry in glioblastoma multiforme. *Proc Natl Acad Sci USA* 2012; **109**: 5316–5321.
33. Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY *et al.* Human embryonic stem cells express a unique set of micromas. *Dev Biol* 2004; **270**: 488–498.
34. Thomson JM, Parker J, Perou CM, Hammond SM. A custom microarray platform for analysis of micromas gene expression. *Nature Met* 2004; **1**: 47–53.
35. Datto MB, Yu Y, Wang XF. Functional analysis of the transforming growth factor beta responsive elements in the *waf1/cip1/p21* promoter. *J Biol Chem* 1995; **270**: 28623–28628.
36. Ohgushi M, Kuroki S, Fukamachi H, O'Reilly LA, Kuida K, Strasser A *et al.* Transforming growth factor beta-dependent sequential activation of *smad*, *bim*, and *caspase-9* mediates physiological apoptosis in gastric epithelial cells. *Mol Cell Biol* 2005; **25**: 10017–10028.
37. Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY *et al.* The myc-mir-17 ~ 92 axis blunts *tgf[β]* signaling and production of multiple *tgf[β]*-dependent antiangiogenic factors. *Cancer Res* 2010; **70**: 8233–8246.
38. Ohyashiki M, Ohyashiki JH, Hirota A, Kobayashi C, Ohyashiki K. Age-related decrease of *mira-92a* levels in human *cd8* + t-cells correlates with a reduction of naive t lymphocytes. *Immunity Ageing* 2011; **8**: 11.
39. Gupta S, Read DE, Deepti A, Cawley K, Gupta A, Oommen D *et al.* Perk-dependent repression of miR-106b-25 cluster is required for er stress-induced apoptosis. *Cell Death Dis* 2012; **3**: e333.
40. Dews M, Homayouni A, Yu D, Murphy D, Seignani C, Wentzel E *et al.* Augmentation of tumor angiogenesis by a myc-activated micromas cluster. *Nat Genet* 2006; **38**: 1060–1065.
41. Wang J, Greene SB, Bonilla-Claudio M, Tao Y, Zhang J, Bai Y *et al.* Bmp signaling regulates myocardial differentiation from cardiac progenitors through a micromas-mediated mechanism. *Dev Cell* 2010; **19**: 903–912.
42. Carraro G, El-Hashash A, Guidolin D, Tiozzo C, Turcatel G, Young BM *et al.* Mir-17 family of micromas controls *fgf10*-mediated embryonic lung epithelial branching morphogenesis through *mapk14* and *stat3* regulation of e-cadherin distribution. *Dev Biol* 2009; **333**: 238–250.
43. Lu Y, Thomson JM, Wong HY, Hammond SM, Hogan BL. Transgenic over-expression of the micromas miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. *Dev Biol* 2007; **310**: 442–453.
44. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J *et al.* Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. *Nat Immunol* 2008; **9**: 405–414.
45. Jiang S, Li C, Olive V, Lykken E, Feng F, Sevilla J *et al.* Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting th1 responses and preventing inducible treg differentiation. *Blood* 2011; **118**: 5487–5497.
46. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F *et al.* A micromas expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA* 2006; **103**: 2257–2261.
47. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A *et al.* Reprogramming of micromas networks in cancer and leukemia. *Genome Res* 2010; **20**: 589–599.
48. Alencar AJ, Malumbres R, Kozloski GA, Advani R, Talreja N, Chinichian S *et al.* Micromas are independent predictors of outcome in diffuse large b-cell lymphoma patients treated with r-chop. *Clin Can Res* 2011; **17**: 4125–4135.
49. Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogdrowski P *et al.* Genetic dissection of the miR-17 ~ 92 cluster of micromas in myc-induced b-cell lymphomas. *Genes Dev* 2009; **23**: 2806–2811.
50. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C *et al.* Mir-19 is a key oncogenic component of miR-17-92. *Genes Dev* 2009; **23**: 2839–2849.
51. van Haften G, Agami R. Tumorigenicity of the miR-17-92 cluster distilled. *Genes Dev* 2010; **24**: 1–4.
52. Moussay E, Wang K, Cho JH, van Moer K, Pierson S, Paggetti J *et al.* Micromas as biomarkers and regulators in B-cell chronic lymphocytic leukemia. *Proc Natl Acad Sci USA* 2011; **108**: 6573–6578.
53. Willmott S, Wagner SD. Stromal cells and *cd40* ligand (*cd154*) alter the micromas and induce micromas clusters including, *mir-125b/mir-99a/let-7c* and *mir-17-92* in chronic lymphocytic leukaemia. *Leukemia* 2012; **26**: 1113–1116.
54. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT *et al.* Distinct micromas expression profiles in acute myeloid leukemia with common translocations. *Proc Natl Acad Sci USA* 2008; **105**: 15535–15540.
55. Meenhuis A, van Veelen PA, de Looper H, van Boxtel N, van den Berge IJ, Sun SM *et al.* Mir-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1-regulated pathways in mice. *Blood* 2011; **118**: 916–925.
56. Diaz-Beya M, Navarro A, Ferrer G, Diaz T, Gel B, Camos M *et al.* Acute myeloid leukemia with translocation (8;16)(p11;p13) and *myst3-crebbp* rearrangement harbors a distinctive micromas signature targeting ret proto-oncogene. *Leukemia* 2012; **27**: 595–603.
57. Wang CL, Wang BB, Bartha G, Li L, Channa N, Klinger M *et al.* Activation of an oncogenic micromas cistron by provirus integration. *Proc Natl Acad Sci USA* 2006; **103**: 18680–18684.
58. Sage J, Ventura A. Mir than meets the eye. *Genes Dev* 2011; **25**: 1663–1667.

59. Conkrite K, Sundby M, Mukai S, Thomson JM, Mu D, Hammond SM *et al.* Mir-17~92 cooperates with rb pathway mutations to promote retinoblastoma. *Genes Dev* 2011; **25**: 1734–1745.
60. Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H *et al.* Over- and under-expressed micromas in human colorectal cancer. *Int J Oncol* 2009; **34**: 1069–1075.
61. Tsuchida A, Ohno S, Wu W, Borjigin N, Fujita K, Aoki T *et al.* Mir-92 is a key oncogenic component of the mir-17-92 cluster in colon cancer. *Cancer Sci* 2011; **102**: 2264–2271.
62. Yu G, Tang JQ, Tian ML, Li H, Wang X, Wu T *et al.* Prognostic values of the mir-17-92 cluster and its paralog in colon cancer. *J Surg Oncol* 2012; **106**: 232–237.
63. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J *et al.* Differential expression of micromas in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. *Gut* 2009; **58**: 1375–1381.
64. Reid JF, Sokolova V, Zoni E, Lampis A, Pizzamiglio S, Bertan C *et al.* Mirna profiling in colorectal cancer highlights mir-1 involvement in met-dependent proliferation. *Mol Can Res* 2012; **10**: 504–515.
65. Gilbertson RJ, Ellison DW. The origins of medulloblastoma subtypes. *Ann Rev Pathol* 2008; **3**: 341–365.
66. Uziel T, Karginov FV, Xie S, Parker JS, Wang YD, Gajjar A *et al.* The mir-17~92 cluster collaborates with the sonic hedgehog pathway in medulloblastoma. *Proc Natl Acad Sci USA* 2009; **106**: 2812–2817.
67. Schulte JH, Marschall T, Martin M, Rosenstiel P, Mestdagh P, Schlierf S *et al.* Deep sequencing reveals differential expression of micromas in favorable versus unfavorable neuroblastoma. *Nucleic Acids Res* 2010; **38**: 5919–5928.
68. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinnazzi S, Forloni M *et al.* Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and bim. *PLoS One* 2008; **3**: e2236.
69. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnoouj A *et al.* Micromas expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. *Oncogene* 2007; **26**: 4442–4452.
70. Morimura R, Komatsu S, Ichikawa D, Takeshita H, Tsujiura M, Nagata H *et al.* Novel diagnostic value of circulating mir-18a in plasma of patients with pancreatic cancer. *Br J Cancer* 2011; **105**: 1733–1740.
71. Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P *et al.* Micromas sequence and expression analysis in breast tumors by deep sequencing. *Cancer Res* 2011; **71**: 4443–4453.
72. Leivonen SK, Makela R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K *et al.* Protein lysate microarray analysis to identify micromas regulating estrogen receptor signaling in breast cancer cell lines. *Oncogene* 2009; **28**: 3926–3936.
73. Yu Z, Willmarth NE, Zhou J, Katlyar S, Wang M, Liu Y *et al.* Micromas 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. *Proc Natl Acad Sci USA* 2010; **107**: 8231–8236.
74. Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Tan AC *et al.* The mir-106b-25 cluster targets smad7, activates tgfbeta signaling, and induces emt and tumor initiating cell characteristics downstream of six1 in human breast cancer. *Oncogene* 2012; **31**: 5162–5171.
75. Fan X, Liu Y, Jiang J, Ma Z, Wu H, Liu T *et al.* Mir-20a promotes proliferation and invasion by targeting app in human ovarian cancer cells. *Acta Biochim Biophys Sin* 2010; **42**: 318–324.
76. Osada H, Takahashi T. Let-7 and mir-17-92: Small-sized major players in lung cancer development. *Cancer Sci* 2011; **102**: 9–17.
77. Chen Q, Si Q, Xiao S, Xie Q, Lin J, Wang C *et al.* Prognostic significance of serum mir-17-5p in lung cancer. *Medical Oncol* 2013; **30**: 353.
78. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC. Circulating micro-rna expression profiles in early stage nonsmall cell lung cancer. *Int J Cancer* 2012; **130**: 1378–1386.
79. Neal CS, Michael MZ, Rawlings LH, Van der Hoek MB, Gleadly JM. The vhl-dependent regulation of micromas in renal cancer. *BMC Med* 2010; **8**: 64.
80. Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Waller T *et al.* Micromas profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. *J Cell Mol Med* 2009; **13**: 3918–3928.
81. Chow TF, Mankarous M, Scorilas A, Youssef Y, Giris A, Mossad S *et al.* The mir-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. *J Urol* 2010; **183**: 743–751.
82. Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant BC, Slagle BL *et al.* Elevated expression of the mir-17-92 polycistron and mir-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. *Am J Pathol* 2008; **173**: 856–864.
83. Shigoka M, Tsuchida A, Matsudo T, Nagakawa Y, Saito H, Suzuki Y *et al.* Dereglulation of mir-92a expression is implicated in hepatocellular carcinoma development. *Pathol Int* 2010; **60**: 351–357.
84. Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG *et al.* Role of the mir-106b-25 micromas cluster in hepatocellular carcinoma. *Cancer Sci* 2009; **100**: 1234–1242.
85. Thayanyth V, Sarver AL, Kartha RV, Li L, Angstadt AY, Breen M *et al.* Perturbation of 14q32 mimas-cmyc gene network in osteosarcoma. *Bone* 2012; **50**: 171–181.
86. Huang G, Nishimoto K, Zhou Z, Hughes D, Kleinerman ES. Mir-20a encoded by the mir-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating fas expression. *Cancer Res* 2012; **72**: 908–916.
87. Taganov KD, Boldin MP, Baltimore D. Micromas and immunity: Tiny players in a big field. *Immunity* 2007; **26**: 133–137.
88. Tsitsiou E, Lindsay MA. Micromas and the immune response. *Curr Opin Pharmacol* 2009; **9**: 514–520.
89. Small EM, Frost RJ, Olson EN. Micromas add a new dimension to cardiovascular disease. *Circulation* 2010; **121**: 1022–1032.
90. Small EM, Olson EN. Pervasive roles of micromas in cardiovascular biology. *Nature* 2011; **469**: 336–342.
91. Fontana L, Pelosi E, Greco P, Racanicchi S, Testa U, Liuzzi F *et al.* Micromas 17-5p-20a-106a control monocytopenia through ami1 targeting and m-csf receptor upregulation. *Nature Cell Biol* 2007; **9**: 775–787.
92. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A *et al.* Micromas-92a controls angiogenesis and functional recovery of ischemic tissues in mice. *Science* 2009; **324**: 1710–1713.
93. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C *et al.* Circulating micromas in patients with coronary artery disease. *Circulation Res* 2010; **107**: 677–684.
94. Tijssen AJ, Pinto YM, Creemers EE. Circulating micromas as diagnostic biomarkers for cardiovascular diseases. *Am J Physiol Heart Circ Physiol* 2012; **303**: H1085–H1095.
95. Diehl P, Fricke A, Sander L, Stamm J, Bassler N, Htun N *et al.* Microparticles: major transport vehicles for distinct micromas in circulation. *Cardiovascular Res* 2012; **93**: 633–644.
96. Hebert SS, De Strooper B. Alterations of the micromas network cause neurodegenerative disease. *Trends Neurosci* 2009; **32**: 199–206.
97. Schonrock N, Matamales M, Ittner LM, Gotz J. Micromas networks surrounding app and amyloid-beta metabolism—implications for alzheimer’s disease. *Exp Neurol* 2012; **235**: 447–454.
98. Otaegui D, Baranzini SE, Armañanzas R, Calvo B, Muñoz-Culla M, Khankhanian P *et al.* Differential micro rna expression in pbmc from multiple sclerosis patients. *PLoS One* 2009; **4**: e6309.
99. Lindberg RL, Hoffmann F, Mehling M, Kuhle J, Kappos L. Altered expression of mir-17-5p in cd4+ lymphocytes of relapsing-remitting multiple sclerosis patients. *Eur J Immunol* 2010; **40**: 888–898.
100. Cox MB, Cairns MJ, Gandhi KS, Carroll AP, Moscovis S, Stewart GJ *et al.* Consortium ANMSG. Micromas mir-17 and mir-20a inhibit t cell activation genes and are under-expressed in ms whole blood. *PLoS One* 2010; **5**: e12132.
101. De Santis G, Ferracin M, Biondani A, Caniatti L, Rosaria Tola M, Castellazzi M *et al.* Altered mirna expression in t regulatory cells in course of multiple sclerosis. *J Neuroimmunol* 2010; **226**: 165–171.
102. Angerstein C, Hecker M, Paap BK, Koczan D, Thamilarasan M, Thiesen HJ *et al.* Integration of micromas databases to study micromas associated with multiple sclerosis. *Mol Neurobiol* 2012; **45**: 520–535.
103. Kapsimali M, Kloosterman WP, de Bruijn E, Rosa F, Plasterk RH, Wilson SW. Micromas show a wide diversity of expression profiles in the developing and mature central nervous system. *Genome Biol* 2007; **8**: R173.
104. Bates DJ, Liang R, Li N, Wang E. The impact of noncoding rna on the biochemical and molecular mechanisms of aging. *Biochim et Biophys Acta* 2009; **1790**: 970–979.
105. Grillari J, Hackl M, Grillari-Voglauer R. Mir-17-92 cluster: Ups and downs in cancer and aging. *Biogerontology* 2010; **11**: 501–506.
106. Hackl M, Brunner S, Fortschegger K, Schreiner C, Micitkova L, Muck C *et al.* mir-19b, mir-20a, and mir-106a are down-regulated in human aging. *Aging Cell* 2010; **9**: 291–296.
107. Lee RC, Feinbaum RL, Ambros V. The *C. elegans* heterochronic gene lin-4 encodes small mas with antisense complementarity to lin-14. *Cell* 1993; **75**: 843–854.
108. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in *C. elegans*. *Cell* 1993; **75**: 855–862.
109. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I. Micromas to nanog, oct4 and sox2 coding regions modulate embryonic stem cell differentiation. *Nature* 2008; **455**: 1124–1128.
110. Brodersen P, Voinnet O. Revisiting the principles of micromas target recognition and mode of action. *Nat Rev Mol Cell Biol* 2009; **10**: 141–148.
111. Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, O’Day E *et al.* Mir-24 inhibits cell proliferation by targeting e2f2, myc, and other cell-cycle genes via binding to ‘seedless’ 3’utr micromas recognition elements. *Mol Cell* 2009; **35**: 610–625.
112. Rigoutsos I, Tsirogas A. *Micromas in Development and Cancer in Molecular Medicine and Medicinal Chemistry*, Slack f (eds) Imperial College Press: Danvers, MA, USA, pp 237–273, 2010.
113. Xia Z, Clark P, Huynh T, Loher P, Zhao Y, Chen HW *et al.* Molecular dynamics simulations of ago silencing complexes reveal a large repertoire of admissible ‘seed-less’ targets. *Sci Rep* 2012; **2**: 569.
114. Ha I, Wightman B, Ruvkun G. A bulged lin-4/lin-14 rna duplex is sufficient for *Caenorhabditis elegans* lin-14 temporal gradient formation. *Genes Dev* 1996; **10**: 3041–3050.
115. Vella MC, Choi EY, Lin SY, Reinert K, Slack FJ. The *C. elegans* micromas let-7 binds to imperfect let-7 complementary sites from the lin-41 3’utr. *Genes Dev* 2004; **18**: 132–137.

116. Easow G, Teleanu AA, Cohen SM. Isolation of microRNA targets by mirnp immunoprecipitation. *RNA* 2007; **13**: 1198–1204.
117. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. *Nature* 2008; **455**: 64–71.
118. Selbach M, Schwanhauser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. *Nature* 2008; **455**: 58–63.
119. Chi SW, Zang JB, Mele A, Darnell RB. Argonaute hits-clip decodes microRNA-mRNA interaction maps. *Nature* 2009; **460**: 479–486.
120. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. *Ann Rev Biochem* 2010; **79**: 351–379.
121. Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P *et al.* Transcriptome-wide identification of miRNA-binding protein and microRNA target sites by par-clip. *Cell* 2010; **141**: 129–141.
122. Thomas M, Lieberman J, Lal A. Desperately seeking microRNA targets. *Nat Struct Mol Biol* 2010; **17**: 1169–1174.
123. Zisoulis DG, Lovci MT, Wilbert ML, Hutt KR, Liang TY, Pasquinelli AE *et al.* Comprehensive discovery of endogenous argonaute binding sites in *Caenorhabditis elegans*. *Nat Struct Mol Biol* 2010; **17**: 173–179.
124. Chi SW, Hannon GJ, Darnell RB. An alternative mode of microRNA target recognition. *Nat Struct Mol Biol* 2012; **19**: 321–327.
125. Skalsky RL, Corcoran DL, Gottwein E, Frank CL, Kang D, Hafner M *et al.* The viral and cellular microRNA targetome in lymphoblastoid cell lines. *PLoS Pathogens* 2012; **8**: e1002484.
126. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM *et al.* A pattern-based method for the identification of microRNA binding sites and their corresponding heteroduplexes. *Cell* 2006; **126**: 1203–1217.
127. Forman JJ, Legesse-Miller A, Collier HA. A search for conserved sequences in coding regions reveals that the let-7 microRNA targets dicer within its coding sequence. *Proc Natl Acad Sci USA* 2008; **105**: 14879–14884.
128. Kloosterman WP, Wienholds E, Ketting RF, Plasterk RH. Substrate requirements for let-7 function in the developing zebrafish embryo. *Nucleic Acids Res* 2004; **32**: 6284–6291.
129. Abdelmohsen K, Srikantan S, Kuwano Y, Gorospe M. Mir-519 reduces cell proliferation by lowering miRNA-binding protein levels. *Proc Natl Acad Sci USA* 2008; **105**: 20297–20302.
130. Rigoutsos I. New tricks for animal microRNAs: Targeting of amino acid coding regions at conserved and nonconserved sites. *Cancer Res* 2009; **69**: 3245–3248.
131. Nelson PT, Wang WX, Mao G, Wilfred BR, Xie K, Jennings MH *et al.* Specific sequence determinants of mir-15/107 microRNA gene group targets. *Nucleic Acids Res* 2011; **39**: 8163–8172.
132. Surdziel E, Cabanski M, Dallmann I, Lyszkiewicz M, Krueger A, Ganser A *et al.* Enforced expression of mir-125b affects myelopoiesis by targeting multiple signaling pathways. *Blood* 2011; **117**: 4338–4348.
133. Adilakshmi T, Sudol I, Tapinos N. Combinatorial action of miRNAs regulates transcriptional and post-transcriptional gene silencing following in vivo PNS injury. *PLoS One* 2012; **7**: e39674.
134. Cui YH, Xiao L, Rao JN, Zou T, Liu L, Chen Y *et al.* Mir-503 represses cug-binding protein 1 translation by recruiting cugbp1 mRNA to processing bodies. *Mol Biol Cell* 2012; **23**: 151–162.
135. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM *et al.* Identification of the mir-106b~25 microRNA cluster as a proto-oncogenic pten-targeting intron that cooperates with its host gene mcm7 in transformation. *Sci Signaling* 2010; **3**: ra29.
136. Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M *et al.* A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. *Cell* 2011; **147**: 358–369.
137. Ambros V, Lee RC, Lavanway A, Williams PT, Jewell D. MicroRNAs and other tiny endogenous RNAs in *C. elegans*. *Curr Biol* 2003; **13**: 807–818.
138. Stark A, Kheradpour P, Parts L, Brennecke J, Hodges E, Hannon GJ *et al.* Systematic discovery and characterization of fly microRNAs using 12 *Drosophila* genomes. *Genome Res* 2007; **17**: 1865–1879.
139. Finnerty JR, Wang WX, Hebert SS, Wilfred BR, Mao G, Nelson PT. The mir-15/107 group of microRNA genes: Evolutionary biology, cellular functions, and roles in human diseases. *J Mol Biol* 2010; **402**: 491–509.
140. Miska EA, Alvarez-Saavedra E, Abbott AL, Lau NC, Hellman AB, McGonagle SM *et al.* Most *Caenorhabditis elegans* microRNAs are individually not essential for development or viability. *PLoS Genet* 2007; **3**: e215.
141. Sokol NS, Xu P, Jan Y-N, Ambros V. *Drosophila* let-7 microRNA is required for remodeling of the neuromusculature during metamorphosis. *Genes Dev* 2008; **22**: 1591–1596.
142. Jackson AL, Levin AA. Developing microRNA therapeutics: Approaching the unique complexities. *Nucleic Acid Ther* 2012; **22**: 213–225.
143. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. *Nature* 2010; **465**: 1033–1038.
144. Rigoutsos I, Furnari F. Gene-expression forum: Decoy for microRNAs. *Nature* 2010; **465**: 1016–1017.
145. Kishore S, Jaskiewicz L, Burger L, Hausser J, Khorshid M, Zavolan M. A quantitative analysis of clip methods for identifying binding sites of miRNA-binding proteins. *Nat Methods* 2011; **8**: 559–564.
146. Leung AK, Young AG, Bhutkar A, Zheng GX, Bosson AD, Nielsen CB *et al.* Genome-wide identification of ago2 binding sites from mouse embryonic stem cells with and without mature microRNAs. *Nat Struct Mol Biol* 2011; **18**: 237–244.
147. Loeb GB, Khan AA, Canner D, Hiatt JB, Shendure J, Darnell RB *et al.* Transcriptome-wide mir-155 binding map reveals widespread noncanonical microRNA targeting. *Mol Cell* 2012; **48**: 760–770.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>

Supplementary Information accompanies this paper on Cell Death and Differentiation website (<http://www.nature.com/cdd>)